Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) announces the publication of its Annual Report for the year ended 31 December 2010. The filing was submitted on 2 March 2011. The document serves as a notification of the availability of the full Annual Report and includes unaudited preliminary results, a consolidated balance sheet, and a cash flow statement. It also details principal risks and uncertainties affecting the Group.
Key Financial Metrics
The following financial data is presented in millions of British Pounds (£m) for the year ended 31 December 2010, compared to 2009:
| Metric | 2010 | 2009 |
|---|---|---|
| Profit After Tax | 1,853 | 5,669 |
| Cash Generated from Operations | 8,631 | 9,545 |
| Net Cash Inflow from Operating Activities | 6,797 | 7,841 |
| Total Assets | 42,230 | 42,862 |
| Total Liabilities | 32,485 | 32,120 |
| Net Assets | 9,745 | 10,742 |
| Shareholders' Equity | 8,887 | 10,005 |
| Long-term Borrowings | 14,809 | 14,786 |
| Short-term Borrowings | 291 | 1,471 |
| Cash and Cash Equivalents | 6,057 | 6,545 |
Note: Revenue figures are not explicitly stated in the provided text, though the filing references "turnover" in the context of specific products and emerging markets.
Material Changes vs. Prior Period
- Profitability Decline: Profit after tax decreased significantly from £5,669 million in 2009 to £1,853 million in 2010. The filing attributes this to material provisions made in 2010 and prior years related to legal proceedings and investigations.
- Debt Reduction: Short-term borrowings decreased substantially from £1,471 million to £291 million, while long-term borrowings remained relatively stable.
- Equity Reduction: Shareholders' equity fell from £10,005 million to £8,887 million, driven by the lower retained earnings (£6,321 million in 2009 vs. £4,779 million in 2010).
- Working Capital: There was a decrease in working capital of £1,297 million in 2010, compared to an increase of £106 million in 2009.
- Reclassifications: Two reclassifications were made during the finalization of the Annual Report, increasing non-current assets by £178 million and current liabilities by £178 million compared to the unaudited preliminary results announced in February 2011.
Guidance, Outlook, Risks, and Unusual Items
Strategic Priorities and Outlook
GSK has established three strategic priorities: growing a diversified business, delivering more products of value, and simplifying its operating model. The company is undertaking a restructuring program with an estimated cost of approximately £4.5 billion, expected to deliver annual pre-tax savings of £2.2 billion by 2012.
Pharmaceutical sales in Emerging Markets grew 22% in 2010 to nearly £3.6 billion, representing 15% of the Group's 2010 pharmaceutical turnover.
Principal Risks and Uncertainties
- R&D and Product Pipeline: Risks regarding the failure of new product candidates to receive regulatory approval or achieve commercial success. Competition from generic manufacturers is intense, particularly in the USA, affecting products like Augmentin, Lamictal IR, Ventolin, and Valtrex.
- Intellectual Property: Threats from generic competition, patent challenges, and potential changes in IP laws (e.g., US healthcare reform reducing exclusivity periods for biologics).
- Legal and Regulatory: Significant exposure to product liability litigation, anti-trust claims, and government investigations into pricing and marketing. The filing notes that unfavorable resolutions could materially affect financial results.
- Pricing Pressures: Increasing pressure from payers and governments in major markets (USA, Europe, Japan) to reduce prices or increase rebates.
- Supply Chain: Risks of supply interruption due to manufacturing non-compliance or third-party supplier failures.
- Geopolitical and Economic: Exposure to global economic conditions, currency fluctuations (USD, Euro, Yen), and political unrest in Middle Eastern and North African markets.
Unusual Items
The filing highlights that the Group has made material provisions in 2010 related to legal proceedings and investigations, which reduced earnings. Additionally, the Group faces increased insurance costs and reduced capacity for coverage due to recent loss experiences.
Investor Verification Checklist
- Legal Provisions: Verify the specific nature and magnitude of the legal provisions impacting the 2010 profit decline.
- Restructuring Costs: Monitor the execution of the £4.5 billion restructuring program and the realization of the projected £2.2 billion annual savings.
- Generic Competition: Assess the impact of generic entry on key products (e.g., Seretide/Advair follow-on) and the timeline for patent expirations.
- Emerging Markets Growth: Confirm the sustainability of the 22% growth rate in Emerging Markets pharmaceutical sales.
- Regulatory Investigations: Track the status of ongoing US federal and state investigations into pricing and marketing practices.
- Reclassifications: Review the detailed impact of the balance sheet and cash flow reclassifications noted in Appendix B.